Opsonic defect in patients with cystic fibrosis of the pancreas.
about
Cystic fibrosis: current concepts.Quantitation of the third component of human complement attached to the surface of opsonized bacteria: opsonin-deficient sera and phagocytosis-resistant strains.Bactericidal mechanisms in rabbit alveolar macrophages: evidence against peroxidase and hydrogen peroxide bactericidal mechanismsInteractions of Pseudomonas aeruginosa with immunoglobulins and complement in sputumRole of lysozyme in the microbicidal activity of rat alveolar macrophages.Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies.Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosisNovel lipophilic probe for detecting near-membrane reactive oxygen species responses and its application for studies of pancreatic acinar cells: effects of pyocyanin and L-ornithineComplement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis.Effects of serum on membrane transport. I. Separation and preliminary characterization of factors which depress lysine or stimulate adenosine transport in rabbit alveolar macrophagesTemperature-sensitive mutants of Pseudomonas aeruginosa: isolation and preliminary immunological evaluationPhagocytosis of Pseudomonas aeruginosa by polymorphonuclear leukocytes and monocytes: effect of cystic fibrosis serum.Immunological abnormalities in cystic fibrosis: chicken or egg?Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assayNutrition and immunity in cystic fibrosis.Pseudomonas aeruginosa infections.Human leucocytes and infection.Functional characterization of macrophage receptors for in vitro phagocytosis of unopsonized Pseudomonas aeruginosaNonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis.The patterns of infection in cystic fibrosis.
P2860
Q33586159-7BA91ED9-5683-4452-B142-2CD4DEEDDEC5Q34099154-9C75E42E-4684-421A-88B0-920CFDE1703BQ34398822-67389654-3C0E-49A6-9618-267BA17FD389Q34399472-D4442A1E-36CC-4A36-B576-052A3238E2F0Q34410586-7F03328A-B916-44CD-9394-0B8659158772Q34472821-12ECC0EA-9819-489C-9872-5E430BC49B99Q34612136-090F4F11-E4CD-4C1E-A143-7D05AB6F1329Q35068471-BB94B8E2-15F9-473B-A245-98F50E9D5F01Q35816211-D18512DF-DF2E-4232-9676-8C9CC9E0EC52Q36272756-CD12D153-8627-48F3-95D7-33DAECC9CEC9Q36335115-24FEE8D5-6ACE-4780-969E-1E9330BE5F8EQ36338321-6846E0F6-CFF6-4CA1-9627-41BEC5B3CB83Q36465502-4ACF46F8-3835-4829-A605-8D7E8F7B49EDQ37004057-B80DE0D1-6C5D-4446-BE3C-ECF1966BA04AQ39675888-8A659161-F88E-4DBB-90CC-103CD4816171Q39903765-1A8C231C-CC72-48EE-B678-28266128AA3FQ39942345-5D244C1F-0579-47F3-AEBF-443418BA49B0Q40378073-7CEA3B0E-CC09-49AB-A4C8-BF263466018FQ40380475-1318D36F-32F6-4CC5-88C0-EF1CF94C3BE9Q40844459-18AE18A2-0251-4696-A5B6-3D38B857C5DEQ43974032-182DEDB5-9303-48CD-ADBC-41712EF329F2
P2860
Opsonic defect in patients with cystic fibrosis of the pancreas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1971
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Opsonic defect in patients with cystic fibrosis of the pancreas.
@en
Opsonic defect in patients with cystic fibrosis of the pancreas.
@nl
type
label
Opsonic defect in patients with cystic fibrosis of the pancreas.
@en
Opsonic defect in patients with cystic fibrosis of the pancreas.
@nl
prefLabel
Opsonic defect in patients with cystic fibrosis of the pancreas.
@en
Opsonic defect in patients with cystic fibrosis of the pancreas.
@nl
P2093
P2860
P921
P356
P1476
Opsonic defect in patients with cystic fibrosis of the pancreas.
@en
P2093
P2860
P304
P356
10.1073/PNAS.68.8.1716
P407
P577
1971-08-01T00:00:00Z